KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Revenue (2016 - 2025)

Historic Revenue for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to $7.5 million.

  • Xenon Pharmaceuticals' Revenue changed N/A to $7.5 million in Q1 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $9.4 million for FY2022, which is 4883.12% down from last year.
  • Xenon Pharmaceuticals' Revenue amounted to $7.5 million in Q1 2025.
  • Xenon Pharmaceuticals' Revenue's 5-year high stood at $8.8 million during Q1 2022, with a 5-year trough of $132000.0 in Q3 2022.
  • For the 3-year period, Xenon Pharmaceuticals' Revenue averaged around $4.0 million, with its median value being $4.0 million (2021).
  • Over the last 5 years, Xenon Pharmaceuticals' Revenue had its largest YoY gain of 10114.73% in 2022, and its largest YoY loss of 9706.67% in 2022.
  • Xenon Pharmaceuticals' Revenue (Quarter) stood at $3.7 million in 2021, then crashed by 96.47% to $132000.0 in 2022, then skyrocketed by 5581.82% to $7.5 million in 2025.
  • Its Revenue was $7.5 million in Q1 2025, compared to $132000.0 in Q3 2022 and $536000.0 in Q2 2022.